Roundup After the Supreme Court: What Remains
In 2024 the Supreme Court narrowed Roundup liability sharply. Three years on, the biggest mass tort in the country has not ended — it has changed shape, and the remaining route to a verdict is narrower and harder than the one plaintiffs began with.
The short version
The Supreme Court’s 2024 decision in Bayer v. Monsanto did not end the Roundup litigation. It removed one of the two ways a plaintiff could get a verdict, leaving the other intact. That is why the largest agricultural mass tort in the United States is still generating trials three years on, and why settlement payments continue.
What the Supreme Court decided
Two holdings matter here, and they are routinely conflated.
Failure to warn is not available as a claim. The Court held that when a product’s warning is different from what a jury concludes is reasonable, that difference does not by itself make the label defective as a matter of law. The reasoning is that a reasonable-warning requirement does not create a freestanding duty to warn beyond what the law imposes, and that the case had to be decided on the state-law question the Court declined.
The practical effect: a plaintiff cannot now win by arguing that Roundup’s label was less cautionous than a jury thought it should have been.
Preemption was resolved. The Court addressed the question of whether federal law pre-empted state failure-to-warn requirements for a product carrying a federally compliant label. That question is now closed.
What the Court did not decide is as important. Design defect — the theory that the product is unreasonably dangerous because of its composition — was not before the Court on that question and was left available. The complaint against Roundup changed shape rather than disappearing.
The distinction that carries the remaining cases
Two theories, routinely confused in coverage:
Failure to warn. The label should have said more. Removed as a general route after 2024.
Design defect. The product should not have been made this way at all, regardless of what the label said. Intact. This is what the remaining trials are about.
The distinction matters because it changes what a plaintiff has to prove. A warning case asks what a reasonable reader would have done with the label. A design case asks whether a safer alternative formulation existed and was feasible — a fact question about chemistry, alternatives and regulatory history, and correspondingly harder to win.
The docket
The litigation is consolidated as MDL No. 2741, In re: Roundup Products Liability Litigation in the Eastern District of Missouri, before Judge Nancy Drain. It is among the largest mass torts ever filed; the pending count has historically run to tens of thousands of cases.
Reported settlement totals are large — above $10 billion cumulatively, with a substantial further settlement announced in early 2026 addressing non-Hodgkin lymphoma claims, subject to court approval. Individual verdicts have ranged from very large to comparatively modest, which is ordinary for a docket this size and is a function of how much proof each individual plaintiff can bring.
Because figures here move and are reported inconsistently across outlets, treat any single number as needing a date attached to it. The JPML’s own statistical report for the docket is the authoritative count of pending cases; company settlement announcements are the authoritative source for what has been paid.
Why it has not wound down
The design-defect theory survives, and it is being tried.
Claims keep arriving within the limitations period. The exposure window for agricultural use is long, and the filings are not all from a single cohort.
Settlement is administratively slow at this scale. Paying tens of thousands of claimants requires a claims process, and eligibility disputes take years.
Appellate litigation continues. Post-verdict appeals in individual cases keep the questions alive and produce new written opinions, each of which can be argued to narrow or widen what remains available.
Where it goes next
The honest answer is that the mass of claims will be resolved by settlement rather than trial, because that is how mass torts end. What the remaining trials will determine is the per-claim value of the design-defect route, and that number will substantially set what a settlement for comparable cases is worth.
Two things would change the picture materially: a state appellate decision construing the Supreme Court’s holding in a way that narrows design defect further, and any Supreme Court decision on the design-defect theory itself. Neither had happened as of this writing.
How to read coverage of this docket
Roundup coverage has a recurring error: reporting the dollar figure as though it were the end of the litigation. A settlement that resolves claims already filed leaves the docket running for everyone not covered by it. Ask which claims a figure covers, and over what period.
The second recurring error is treating the Supreme Court decision as a dismissal. It was a narrowing of one theory, not an ending.
Nothing here is legal advice
This is an explanation of where a large public litigation stands and what its remaining legal questions are. It is not legal advice, and it cannot tell you whether an individual Roundup claim is viable, timely, or worth pursuing. Limitations periods in this litigation have been contested, and whether one has run depends on facts and law specific to the claimant. That requires a licensed attorney.
For the docket itself, the JPML MDL 2741 statistical report and the Eastern District of Missouri case records are the authoritative sources.
Topics
Frequently asked questions
Is the Roundup litigation over?
No. Bayer has settled a very large number of claims — reported well above $10 billion — and the failure-to-warn theory has been removed as a route to liability. But the docket continues, with trials proceeding on a narrower design-defect theory and settlements still being paid out. It is winding down in volume without being finished.
What did the Supreme Court actually decide?
In Bayer v. Monsanto (2024) the Court held that a product label warning that differs from what a jury finds reasonable is not a failure-to-warn defect as a matter of law, because the label was not deficient. The decision also addressed preemption. It did not decide whether Roundup can be found defectively designed — that theory was left available to proceed.
Why do plaintiffs still have a theory if warning claims are gone?
Because design defect and failure to warn are different claims. A design-defect claim asserts that the product is unreasonably dangerous because of how it is made, independent of what the label said. That theory survived the decision, which is why trials have continued.
What is at stake for an individual claimant?
Two things, in order of importance: whether the statute of limitations has run, and which theory the claim is pleaded under. Deadlines in this litigation have been contested and the limitations analysis is fact-specific. Nothing here is legal advice and nothing here tells you whether an individual claim is viable.
Sources and references
- Bayer v. Monsanto Co., 604 U.S. ___ (2024) — opinion — Supreme Court of the United States, accessed 2026-10-04
- In re: Roundup Products Liability Litigation (MDL No. 2741) — CourtListener / RECAP, accessed 2026-10-04
- Panel on Multidistrict Litigation — MDL 2741 statistical report — United States Judicial Panel on Multidistrict Litigation, accessed 2026-10-04
Case enquiry
Ask about Roundup After the Supreme Court: What Remains
Send your details and we will reply within one working day. Three short steps — you can go back at any point.
No obligation. We do not share your details.